The Effects of Short-Term Exenatide Therapy in Newly Diagnosed Type 2 Diabetic Patients
Status:
Unknown status
Trial end date:
2015-12-01
Target enrollment:
Participant gender:
Summary
Whether GLP-1 and GLP-1 receptor agonists will produce a sustained improvement in beta-cell
function following short-term therapy is currently not known. This randomized, controlled
trial is carried to assess the efficacy of short-term insulin therapy (NPH injection twice
daily) compared with GLP-1 analogue (Exenatide injection twice daily) on glycemic control,
remission rate, ß-cell function, and long-term glycemic control in newly diagnosed type 2
diabetic patients with moderate hyperglycemia.